EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease

Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. Molecules. 2021.

Organ: brain-cognition · Type: review · Peptides: EDR

A 2021 open-access review of how the tripeptide EDR has been proposed to touch AD-related gene-expression and protein-synthesis pathways — not a trial, and not evidence that EDR treats Alzheimer’s disease.

Editorial summary of a 2021 Molecules review (MDPI, open access: doi:10.3390/molecules26010159; published 31 December 2020). Narrative review of prior EDR work. Public pages cite PubMed; the DOI is the OA record. Read the paper: PMID 33396470.

Methods

Narrative review. The authors compile previously published in-vitro and in-vivo observations on Glu-Asp-Arg (EDR, also discussed in this literature as Pinealon) — neuronal cultures, antioxidant-enzyme readouts, dendritic-spine morphology in Alzheimer and Huntington models, animal behavior, and a mention of memory scores in elderly patients from earlier papers. They then outline a hypothetical intracellular path: peptide entry, contact with histones and/or RNA, and downstream effects on MAPK/ERK, caspase-3, p53, SOD2, GPX1, PPARA/PPARG, serotonin, and calmodulin. No new patient cohort and no new wet-lab assay is generated by this article itself.

Findings

The authors argue that EDR’s reported neuroprotective properties could run through gene-expression and protein-synthesis nodes that also appear in Alzheimer pathogenesis. They present that as a possible mechanism, not as a demonstrated clinical effect. The paper does not establish that EDR treats or prevents Alzheimer’s disease.

Prospects language is not evidence of effect. Dosing and product use are outside the scope of this page. Follow the PMID and the OA DOI.